| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $489,325 | 8 | 100 |
Sells | $0 | 0 | 0 |
| Patel Snehal | CEO and CFO | 8 | $489,325 | 0 | $0 | $489,325 |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Over the last 12 months, insiders at Greenwich LifeSciences, Inc. have bought $489,325 and sold $0 worth of Greenwich LifeSciences, Inc. stock.
On average, over the past 5 years, insiders at Greenwich LifeSciences, Inc. have bought $1.3M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Patel Snehal (CEO and CFO) — $489,325.
The last purchase of 1,800 shares for transaction amount of $53,694 was made by Patel Snehal (CEO and CFO) on 2026‑01‑13.
| 2026-01-13 | Patel Snehal | CEO and CFO | 1,800 0.0134% | $29.83 | $53,694 | -11.23% | ||
| 2026-01-12 | Patel Snehal | CEO and CFO | 2,900 0.0215% | $27.54 | $79,866 | -3.95% | ||
| 2025-12-31 | Patel Snehal | CEO and CFO | 4,300 0.0303% | $21.36 | $91,848 | +22.23% | ||
| 2025-12-30 | Patel Snehal | CEO and CFO | 2,900 0.0208% | $21.73 | $63,017 | +16.67% | ||
| 2025-12-18 | Patel Snehal | CEO and CFO | 4,100 0.0302% | $12.62 | $51,742 | +104.04% | ||
| 2025-11-25 | Patel Snehal | CEO and CFO | 4,600 0.0341% | $8.37 | $38,502 | +196.19% | ||
| 2025-11-07 | Patel Snehal | CEO and CFO | 10,600 0.0712% | $8.43 | $89,358 | +182.79% | ||
| 2025-10-31 | Patel Snehal | CEO and CFO | 2,300 0.0169% | $9.26 | $21,298 | +162.38% | ||
| 2025-04-25 | Patel Snehal | CEO and CFO | 3,600 0.0271% | $9.88 | $35,568 | +12.93% | ||
| 2025-04-17 | Patel Snehal | CEO and CFO | 5,400 0.0385% | $8.98 | $48,492 | +25.20% | ||
| 2025-04-07 | Patel Snehal | CEO and CFO | 3,600 0.026% | $9.10 | $32,760 | +14.60% | ||
| 2025-04-04 | Patel Snehal | CEO and CFO | 5,500 0.0414% | $8.73 | $48,015 | +24.24% | ||
| 2025-01-10 | Patel Snehal | CEO and CFO | 2,500 0.0191% | $12.51 | $31,275 | -13.41% | ||
| 2025-01-07 | Patel Snehal | CEO and CFO | 1,800 0.0138% | $13.75 | $24,750 | -22.38% | ||
| 2025-01-06 | Patel Snehal | CEO and CFO | 1,100 0.0084% | $13.31 | $14,641 | -18.23% | ||
| 2025-01-03 | Patel Snehal | CEO and CFO | 3,400 0.0253% | $12.95 | $44,030 | -16.85% | ||
| 2025-01-02 | Patel Snehal | CEO and CFO | 2,000 0.0154% | $11.97 | $23,940 | -8.69% | ||
| 2024-12-31 | Patel Snehal | CEO and CFO | 2,400 0.0181% | $11.36 | $27,264 | -4.54% | ||
| 2024-12-30 | Patel Snehal | CEO and CFO | 3,200 0.0235% | $11.12 | $35,584 | -1.74% | ||
| 2024-11-21 | Thompson Jaye | VP Clinical Reg Affairs | 1,000 0.0077% | $12.91 | $12,910 | -14.07% |
| Patel Snehal | CEO and CFO | 5604102 38.1797% | $124.69M | 79 | 0 | +0.51% |
| McWilliams David | director | 620301 4.226% | $13.8M | 3 | 0 | <0.0001% |
| Hallock Kenneth | director | 397304 2.7068% | $8.84M | 4 | 0 | <0.0001% |
| Rothe Eric | director | 313226 2.134% | $6.97M | 1 | 0 | |
| Thompson Jaye | VP Clinical Reg Affairs | 264148 1.7996% | $5.88M | 21 | 0 | <0.0001% |
| Daugherty Frank Joseph | Chief Medical Officer | 90121 0.614% | $2.01M | 5 | 0 | <0.0001% |
Greenwich LifeSciences, Inc. (GLSI) | $6,125,624 | 95 | -6.06% | $326.59M |
$17,468,215 | 46 | 18.85% | $303.9M | |
$64,573,910 | 36 | -14.02% | $303.72M | |
$63,049,419 | 31 | 2.87% | $302.01M | |
$22,017,898 | 24 | 39.19% | $363.95M | |
$3,668,031 | 23 | 2.05% | $311.19M | |
$15,467,825 | 18 | 4.98% | $362.62M | |
$104,137,421 | 15 | 21.28% | $300.28M | |
$101,822,203 | 13 | 84.03% | $329.58M | |
$5,529,561 | 8 | 5.30% | $316.52M | |
$17,675,244 | 7 | 92.20% | $357.82M | |
$556,839 | 5 | 13.42% | $318.88M | |
$208,592 | 4 | 11.22% | $328.02M | |
$51,688 | 4 | -26.18% | $361.24M | |
$184,294 | 3 | -10.64% | $340.12M | |
$10,104,842 | 3 | 5.45% | $343.14M | |
$37,067 | 3 | -89.81% | $302.03M | |
$20,020,000 | 1 | -75.24% | $327.12M | |
$3,850,000 | 1 | -51.32% | $314.32M |
| Increased Positions | 23 | +38.33% | 243,887 | +20.09% |
| Decreased Positions | 25 | -41.67% | 131,031 | -10.79% |
| New Positions | 7 | New | 164,979 | New |
| Sold Out Positions | 8 | Sold Out | 86,224 | Sold Out |
| Total Postitions | 58 | -3.33% | 1M | +9.29% |
| Blackrock, Inc. | $7,073.00 | 2.6% | 363,299 | -3,882 | -1.06% | 2025-09-30 |
| Vanguard Group Inc | $5,494.00 | 2.02% | 282,181 | +13,179 | +4.9% | 2025-09-30 |
| Geode Capital Management, Llc | $2,767.00 | 1.02% | 142,116 | +3,134 | +2.25% | 2025-09-30 |
| State Street Corp | $1,595.00 | 0.59% | 81,946 | -301 | -0.37% | 2025-09-30 |
| Northern Trust Corp | $1,478.00 | 0.54% | 75,905 | -6,874 | -8.3% | 2025-09-30 |
| Renaissance Technologies Llc | $748.00 | 0.27% | 38,400 | +11,100 | +40.66% | 2025-09-30 |
| Marshall Wace, Llp | $624.00 | 0.23% | 32,051 | -24,091 | -42.91% | 2025-09-30 |
| Deutsche Bank Ag | $419.00 | 0.15% | 21,502 | +21,502 | New | 2025-09-30 |
| Citadel Advisors Llc | $408.00 | 0.15% | 20,942 | +7,174 | +52.11% | 2025-09-30 |
| Strs Ohio | $389.00 | 0.14% | 20,000 | 0 | 0% | 2025-09-30 |